文献速递临床试验与 GCP真实世界研究与卫生经济

八味地黄丸辅助治疗慢性腰痛的随机对照试验方案

Efficacy, safety, and cost-effectiveness analysis of adjuvant herbal medicine treatment, Palmijihwang-hwan, for chronic low back pain: a study protocol for randomized, controlled, assessor-blinded, multicenter clinical trial.
PubMed 文献 · Trials · 2019-12-27

本研究为随机、评估者盲法、多中心临床试验方案,在四家韩医学医院招募84例慢性腰痛患者,按1:1随机分为对照组(单纯针刺)和试验组(针刺加八味地黄丸),干预6周,主要结局为VAS评分变化,并评估安全性及成本效果。

要点

  • 八味地黄丸辅助针刺治疗慢性腰痛的有效性、安全性和成本效果尚缺乏证据。
  • 主要结局为基线至干预完成时VAS评分变化,次要结局包括疼痛临床相关改善、功能障碍、生活质量、整体评估和经济分析。
  • 试验采用评估者盲法,但缺乏安慰剂对照是主要局限性。

核心结论

  • 本试验将提供八味地黄丸治疗慢性腰痛的临床证据。

研究设计与样本

  • 随机、评估者盲法、多中心、两组平行对照临床试验。
  • 四家韩医学医院招募84例参与者,按1:1随机分配至对照组或试验组。
  • 对照组接受针刺治疗(11个局部和4个远端穴位,每次20分钟,每周两次,共6周);试验组接受相同针刺并加用八味地黄丸6周。

关键数值与推荐

  • 主要结局为基线(第1次访视)至干预完成(第12次访视)的VAS评分变化。
  • 次要结局包括VAS改善≥30%或≥50%的参与者比例、Roland and Morris功能障碍问卷、EuroQol-5D、患者整体印象变化、成本效果和成本效用分析及安全性评估。

局限性

  • 缺乏安慰剂对照。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Low back pain is a common symptom and continuous or recurrent pain results in chronic low back pain (CLBP). While many patients with CLBP have tried various treatments, complementary and alternative medicine including acupuncture and herbal medicine is one of the commonly used treatments. Palmijihwang-hwan is a herbal medicine used frequently in clinical practice but there has been no report of the efficacy, safety, or cost-effectiveness analysis of Palmijihwang-hwan for CLBP. METHODS: This study is a randomized, assessor-blinded, multicenter, clinical trial with two parallel groups. Four Korean medicine hospitals will recruit 84 participants and randomly allocate them into the control or treatment group in a 1:1 ratio. The control group will receive acupuncture treatment at 11 local and 4 distal acupuncture points for 20 min twice a week for 6 weeks. The treatment group will receive the same acupuncture treatment as the control group and also take Palmijihwang-hwan for 6 weeks. The primary outcome will be the change in visual analog scale (VAS) score between baseline (visit 1) and completion of the intervention (visit 12), and secondary outcomes will be pain-related clinical relevance (minimal clinical important difference or the proportion of the participants who decrease more than 30, or 50% on VAS), disability (Roland and Morris Disability Questionnaire), quality of life (EuroQol-5D), global assessment (Patient Global Impression of Change), and economic analysis (cost-effectiveness and cost-utility analysis). Additionally, safety will be assessed. DISCUSSION: The results of our study will provide the clinical evidence about the efficacy, safety, and cost-effectiveness analysis of Palmijihwang-hwan for CLBP. There will be a chance to provide multiple subdivided influence of this treatment with various outcome measures, but lack of placebo is our limitation. TRIAL REGISTRATION: Clinical Research Information Service, KCT0002998. Registered on 12 July 2018.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Sung WS, Jeon SR, Hong YJ, et al. Efficacy, safety, and cost-effectiveness analysis of adjuvant herbal medicine treatment, Palmijihwang-hwan, for chronic low back pain: a study protocol for randomized, controlled, assessor-blinded, multicenter clinical trial. Trials. 2019. PMID: 31882016. doi:10.1186/s13063-019-3776-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。